Aura Biosciences (AURA) Payables (2020 - 2026)
Aura Biosciences' (AURA) quarterly Payables came in at $2.6 million in Q1 2026, up 28.27% YoY from $2.0 million in Q1 2025, and up 66.11% on a QoQ basis from $1.5 million in Q4 2025.
Aura Biosciences (AURA) Payables (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Payables data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Payables rose 28.27% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 28.27% YoY) and the FY2025 annual result came in at $1.5 million, down 32.77% from the prior year.
- Payables climbed to $2.6 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Payables ranged from a high of $2.9 million in Q4 2022 to a low of $553000.0 in Q2 2023.
- A 5-year average of $1.7 million and a median of $1.8 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables tumbled 53.84% — and 2024, when it jumped 163.83%.
- Tracing AURA's Payables over 5 years: stood at $2.9 million in 2022, then plunged by 38.82% to $1.8 million in 2023, then climbed by 28.93% to $2.3 million in 2024, then sank by 32.77% to $1.5 million in 2025, then jumped by 66.11% to $2.6 million in 2026.
- The last three Payables figures came in at $2.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.25 Mn |
| Mar 31, 2026 | 2.57 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 1.79 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 553,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Mar 31, 2022 | 1.96 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 1.74 Mn |